A Retrospective Study: The Effectiveness of Lipid-Lowering Medications in Individuals at High Risk for Cardiovascular Disease

Fethullah Kayan; Serhat Günlü

Makale detayları

A Retrospective Study: The Effectiveness of Lipid-Lowering Medications in Individuals at High Risk for Cardiovascular Disease

Yazarlar:

Fethullah Kayan | Serhat Günlü

Yayıncı:

Dicle University

Ana Başlıklar:

Tıp Eğitimi

Dergi:

Dicle Tıp Dergisi Vol.51 Issue 1, pp.10-18

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001313024

pISSN:

1300-2945

Anahtar kelimeler:

Özet:

 Objective: The effective administration of lipid-lowering treatment is of utmost importance in mitigating cardiovascular CV risk in patients who are undergoing secondary prevention. High-dose statins, ezetimibe, and the relatively newer PCSK9 inhibitors PCSK9i have shown effectiveness in achieving low density lipoprotein cholesterolLDL-C treatment targets for these patients. However, despite substantial evidence supporting their efficacy, these interventions remain significantly underutilized, primarily due to poor levels of patient adherence. Moreover, there is limited data available on the overall effectiveness of cholesterol-lowering treatment and the proportion of secondary prevention patients who have achieved a well-regulated lipid profile. In light of these factors, the principal aim of this investigation was to evaluate the present status of lipid-lowering medication within this specific group of individuals. Methods: The study was conducted at Mardin Artuklu University, Mardin Training and Research Hospital between April 2021 and March 2023, focusing on patients with a history of secondary prevention of CVD. The study investigated prescribed cholesterol-lowering drugs, factors contributing to statin underuse, and lipid profile disclosure. Results: 872 patients were included. 86.8 received statins, 5.2 ezetimibe, and 3.4 fibrates, while 13.2 received no lipid-lowering therapy. 64 of those on statins were on high doses. LDL-C values were assessed in 452 patients, with only 30 below the recommended cutoff of 70 mgdL. Conclusion: In this investigation involving secondary prevention patients, slightly over half of the participants received high-dose statins, while a negligible proportion received ezetimibe treatment. Alarmingly, over two-thirds of the patients demonstrated LDL-C values that deviated significantly from the therapeutic range, indicating a considerable gap between their lipid profiles and the recommendations set forth by clinical guidelines.

 Objective: The effective administration of lipid-lowering treatment is of utmost importance in mitigating cardiovascular CV risk in patients who are undergoing secondary prevention. High-dose statins, ezetimibe, and the relatively newer PCSK9 inhibitors PCSK9i have shown effectiveness in achieving low density lipoprotein cholesterolLDL-C treatment targets for these patients. However, despite substantial evidence supporting their efficacy, these interventions remain significantly underutilized, primarily due to poor levels of patient adherence. Moreover, there is limited data available on the overall effectiveness of cholesterol-lowering treatment and the proportion of secondary prevention patients who have achieved a well-regulated lipid profile. In light of these factors, the principal aim of this investigation was to evaluate the present status of lipid-lowering medication within this specific group of individuals. Methods: The study was conducted at Mardin Artuklu University, Mardin Training and Research Hospital between April 2021 and March 2023, focusing on patients with a history of secondary prevention of CVD. The study investigated prescribed cholesterol-lowering drugs, factors contributing to statin underuse, and lipid profile disclosure. Results: 872 patients were included. 86.8 received statins, 5.2 ezetimibe, and 3.4 fibrates, while 13.2 received no lipid-lowering therapy. 64 of those on statins were on high doses. LDL-C values were assessed in 452 patients, with only 30 below the recommended cutoff of 70 mgdL. Conclusion: In this investigation involving secondary prevention patients, slightly over half of the participants received high-dose statins, while a negligible proportion received ezetimibe treatment. Alarmingly, over two-thirds of the patients demonstrated LDL-C values that deviated significantly from the therapeutic range, indicating a considerable gap between their lipid profiles and the recommendations set forth by clinical guidelines.

 Objective: The effective administration of lipid-lowering treatment is of utmost importance in mitigating cardiovascular CV risk in patients who are undergoing secondary prevention. High-dose statins, ezetimibe, and the relatively newer PCSK9 inhibitors PCSK9i have shown effectiveness in achieving low density lipoprotein cholesterolLDL-C treatment targets for these patients. However, despite substantial evidence supporting their efficacy, these interventions remain significantly underutilized, primarily due to poor levels of patient adherence. Moreover, there is limited data available on the overall effectiveness of cholesterol-lowering treatment and the proportion of secondary prevention patients who have achieved a well-regulated lipid profile. In light of these factors, the principal aim of this investigation was to evaluate the present status of lipid-lowering medication within this specific group of individuals. Methods: The study was conducted at Mardin Artuklu University, Mardin Training and Research Hospital between April 2021 and March 2023, focusing on patients with a history of secondary prevention of CVD. The study investigated prescribed cholesterol-lowering drugs, factors contributing to statin underuse, and lipid profile disclosure. Results: 872 patients were included. 86.8 received statins, 5.2 ezetimibe, and 3.4 fibrates, while 13.2 received no lipid-lowering therapy. 64 of those on statins were on high doses. LDL-C values were assessed in 452 patients, with only 30 below the recommended cutoff of 70 mgdL. Conclusion: In this investigation involving secondary prevention patients, slightly over half of the participants received high-dose statins, while a negligible proportion received ezetimibe treatment. Alarmingly, over two-thirds of the patients demonstrated LDL-C values that deviated significantly from the therapeutic range, indicating a considerable gap between their lipid profiles and the recommendations set forth by clinical guidelines.

 Objective: The effective administration of lipid-lowering treatment is of utmost importance in mitigating cardiovascular CV risk in patients who are undergoing secondary prevention. High-dose statins, ezetimibe, and the relatively newer PCSK9 inhibitors PCSK9i have shown effectiveness in achieving low density lipoprotein cholesterolLDL-C treatment targets for these patients. However, despite substantial evidence supporting their efficacy, these interventions remain significantly underutilized, primarily due to poor levels of patient adherence. Moreover, there is limited data available on the overall effectiveness of cholesterol-lowering treatment and the proportion of secondary prevention patients who have achieved a well-regulated lipid profile. In light of these factors, the principal aim of this investigation was to evaluate the present status of lipid-lowering medication within this specific group of individuals. Methods: The study was conducted at Mardin Artuklu University, Mardin Training and Research Hospital between April 2021 and March 2023, focusing on patients with a history of secondary prevention of CVD. The study investigated prescribed cholesterol-lowering drugs, factors contributing to statin underuse, and lipid profile disclosure. Results: 872 patients were included. 86.8 received statins, 5.2 ezetimibe, and 3.4 fibrates, while 13.2 received no lipid-lowering therapy. 64 of those on statins were on high doses. LDL-C values were assessed in 452 patients, with only 30 below the recommended cutoff of 70 mgdL. Conclusion: In this investigation involving secondary prevention patients, slightly over half of the participants received high-dose statins, while a negligible proportion received ezetimibe treatment. Alarmingly, over two-thirds of the patients demonstrated LDL-C values that deviated significantly from the therapeutic range, indicating a considerable gap between their lipid profiles and the recommendations set forth by clinical guidelines.

Makale detayları

A Retrospective Study: The Effectiveness of Lipid-Lowering Medications in Individuals at High Risk for Cardiovascular Disease

Yazarlar:

Fethullah Kayan | Serhat Günlü

Yayıncı:

Dicle University

Ana Başlıklar:

Tıp Eğitimi

Dergi:

Dicle Tıp Dergisi Vol.51 Issue 1, pp.10-18

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001313024

pISSN:

1300-2945

Statins

PCKS-9i

Ezetimibe

Low-density lipoprotein cholesterol (LDL-C)

Secondary prevention

Sayı

Makale detayları

A Retrospective Study: The Effectiveness of Lipid-Lowering Medications in Individuals at High Risk for Cardiovascular Disease

Yazarlar: Fethullah Kayan | Serhat Günlü

Yayıncı: Dicle University

Ana Başlıklar: Tıp Eğitimi

Dergi: Dicle Tıp Dergisi Vol.51 Issue 1, pp.10-18

Belge Tipi: Makale

Yayın Tarihi: 3/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001313024

pISSN: 1300-2945

Statins

PCKS-9i

Ezetimibe

Low-density lipoprotein cholesterol (LDL-C)

Secondary prevention

Sayı

Yazarlar:

Fethullah Kayan | Serhat Günlü

Yayıncı:

Dicle University

Ana Başlıklar:

Tıp Eğitimi

Dergi:

Dicle Tıp Dergisi Vol.51 Issue 1, pp.10-18

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001313024

pISSN:

1300-2945